Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Janux Therapeutics Inc (JANX)

Janux Therapeutics Inc (JANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 860,718
  • Shares Outstanding, K 60,148
  • Annual Sales, $ 10,590 K
  • Annual Income, $ -68,990 K
  • EBIT $ -144 M
  • EBITDA $ -153 M
  • 60-Month Beta 2.82
  • Price/Sales 80.21
  • Price/Cash Flow N/A
  • Price/Book 0.87

Options Overview Details

View History
  • Implied Volatility 66.09% (-5.97%)
  • Historical Volatility 224.87%
  • IV Percentile 3%
  • IV Rank 13.35%
  • IV High 181.74% on 11/25/25
  • IV Low 48.27% on 12/27/24
  • Expected Move (DTE 21) 1.66 (11.58%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,050
  • Volume Avg (30-Day) 2,428
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 20,051
  • Open Int (30-Day) 31,552
  • Expected Range 12.65 to 15.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 9
  • High Estimate -0.56
  • Low Estimate -0.78
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -80.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.76 +4.00%
on 12/19/25
35.34 -59.51%
on 11/26/25
-17.22 (-54.61%)
since 11/24/25
3-Month
13.76 +4.00%
on 12/19/25
35.34 -59.51%
on 11/26/25
-8.53 (-37.35%)
since 09/24/25
52-Week
13.76 +4.00%
on 12/19/25
61.59 -76.77%
on 01/07/25
-41.83 (-74.51%)
since 12/24/24

Most Recent Stories

More News
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager...

JANX : 14.31 (+1.35%)
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential

These two biotech disruptors are poised for triple-digit breakout gains.

KYTX : 8.99 (+1.24%)
JANX : 14.31 (+1.35%)
$SPX : 6,932.05 (+0.32%)
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated...

JANX : 14.31 (+1.35%)
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

The virtual event will take place on Monday, December 1, 2025, at 4:30 PM ET

JANX : 14.31 (+1.35%)
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 ...

JANX : 14.31 (+1.35%)
Janux Therapeutics Inc (JANX) Gets a Buy from Truist Financial

Truist Financial analyst initiated coverage with a Buy rating on Janux Therapeutics Inc yesterday and set a price target of $100.00. The company’s shares closed yesterday at $22.76.Elevate Your Investing...

JANX : 14.31 (+1.35%)
Janux Therapeutics Inc (JANX) Gets a Buy from Bank of America Securities

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Janux Therapeutics Inc today. The company’s shares closed yesterday at $23.31.Elevate Your Investing Strategy: Take advantage...

JANX : 14.31 (+1.35%)
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases ...

JANX : 14.31 (+1.35%)
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux

JANX : 14.31 (+1.35%)
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth...

JANX : 14.31 (+1.35%)

Business Summary

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

See More

Key Turning Points

3rd Resistance Point 14.93
2nd Resistance Point 14.71
1st Resistance Point 14.51
Last Price 14.31
1st Support Level 14.09
2nd Support Level 13.87
3rd Support Level 13.67

See More

52-Week High 61.59
Fibonacci 61.8% 43.32
Fibonacci 50% 37.67
Fibonacci 38.2% 32.03
Last Price 14.31
52-Week Low 13.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar